Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

667
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
667
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

124
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
124
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

151
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
151
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

114
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
114
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

72
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
72

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Soluble Receptor for Advanced Glycation End-Products Attenuates Myocardial Ischemia/Reperfusion Injury via Enhancing Glucose Metabolism.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2025
Same author

Apelin Alleviated Endothelial-To-Mesenchymal Transition via Increasing BKCa in Diabetic Nephropathy.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2025
Same author

Apelin-13 inhibits ischemia-reperfusion mediated podocyte apoptosis by reducing m-TOR phosphorylation to enhance autophagy.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2025
Same author

Protective Effects of the Soluble Receptor for Advanced Glycation End-Products on Pyroptosis during Myocardial Ischemia-Reperfusion.

Oxidative medicine and cellular longevity·2021
Same author

COX-2 inhibition improves immune system homeostasis and decreases liver damage in septic rats.

The Journal of surgical research·2009
Same author

Mass spectral characterization of organophosphate-labeled, tyrosine-containing peptides: characteristic mass fragments and a new binding motif for organophosphates.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2009

Related Experiment Video

Updated: Nov 19, 2025

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

422

Apelin/APJ relieve diabetic cardiomyopathy by reducing microvascular dysfunction.

Bin Li1, Jiming Yin2,3, Jing Chang2

  • 1School of Basic Medical Sciences, Capital Medical University, Beijing, China.

The Journal of Endocrinology
|January 28, 2021
PubMed
Summary

Apelin peptide improves endothelial cell function, reducing cardiac microvascular damage in diabetes. This finding offers a potential therapeutic strategy for diabetic cardiomyopathy by targeting endothelial dysfunction.

Keywords:
APJapelindiabetic cardiomyopathyendothelial dysfunctionmicrocirculatory injuries

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.1K
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

6.7K

Related Experiment Videos

Last Updated: Nov 19, 2025

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

422
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.1K
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

6.7K

Area of Science:

  • Cardiovascular Biology
  • Endocrinology
  • Molecular Medicine

Background:

  • Diabetic cardiomyopathy is linked to microcirculatory injuries, primarily endothelial cell dysfunction.
  • Apelin, an adipokine elevated in diabetes, shows potential in improving endothelial function and mitigating cardiac issues.

Purpose of the Study:

  • To investigate the role of apelin in alleviating endothelial cell dysfunction and subsequent diabetic cardiomyopathy.
  • To elucidate the molecular mechanisms underlying apelin's effects on endothelial cells in diabetes.

Main Methods:

  • Assessed apelin's impact on endothelial cell apoptosis, proliferation, angiogenesis, and adhesion molecule expression.
  • Utilized endothelial cell-specific APJ knockout mice and in vitro cell cultures.
  • Investigated the involvement of APJ receptor and NFκB pathways.

Main Results:

  • Apelin treatment enhanced endothelial cell proliferation, angiogenesis, and E-cadherin/VEGFR 2/Tie-2 expression while decreasing apoptosis and adhesion molecules.
  • Apelin reduced cardiac microvascular permeability and attenuated diabetic cardiomyopathy.
  • Apelin's beneficial effects on endothelial cells were confirmed to be APJ-dependent and involve NFκB signaling.

Conclusions:

  • Apelin ameliorates endothelial dysfunction in diabetic cardiomyopathy by improving endothelial cell function and integrity.
  • The protective effects of apelin are mediated through the APJ receptor and downstream NFκB pathways.
  • Apelin represents a promising therapeutic target for managing diabetic microvascular complications and cardiomyopathy.